Pregnancy outcome following second-trimester amniocentesis: A case-control study

American Journal of Perinatology

Volumn 23, Issue 1, 2006, Pages 25-30

  Müngen, Ercüment ^a,b   Tütüncü, Levent ^b   Muhcu, Murat ^b   Yergök, Yusuf Ziya ^b  

^a Arzu Apt No 2/11 ^*  (Turkey)

^b GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

Author keywords

Fetal loss; Pregnancy outcome; Second trimester amniocentesis

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; AMNIOCENTESIS; ANEUPLOIDY; ANXIETY; ARTICLE; CASE CONTROL STUDY; CESAREAN SECTION; CHROMOSOME ABERRATION; CONTROLLED STUDY; CORDOCENTESIS; ECLAMPSIA; FEMALE; FETUS DEATH; FETUS WASTAGE; FISHER EXACT TEST; HUMAN; KARYOTYPING; MAJOR CLINICAL STUDY; MATERNAL AGE; MATERNAL SERUM; NUCHAL TRANSLUCENCY MEASUREMENT; PARITY; PREECLAMPSIA; PREGNANCY OUTCOME; PREMATURE LABOR; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; SECOND TRIMESTER PREGNANCY; SOLUTIO PLACENTAE; SPONTANEOUS ABORTION; STATISTICAL ANALYSIS; STILLBIRTH; TREATMENT INDICATION; TRISOMY 13; TRISOMY 18; TRISOMY 21; TURNER SYNDROME;

ADOLESCENT; ADULT; AMNIOCENTESIS; CASE-CONTROL STUDIES; CYTOGENETIC ANALYSIS; FEMALE; HUMANS; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, SECOND;

EID: 32244433391     PISSN: 07351631     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-923432     Document Type: Article

References (22)

1. Tabor A, Philip J, Madsen M, Bang J, Obel EB, Norgaard-Pedersen B. Randomised controlled trial of genetic amniocentesis in 4606 low-risk women. Lancet 1986;1:1287-1293
2. An assessment of the hazards of amniocentesis: report to the Medical Research Council by their Working Party on amniocentesis. Br J Obstet Gynaecol 1978;85(suppl 2):1-41
3. Muller F, Thibaud D, Poloce F, et al. Risk of amniocentesis in women screened positive for Down syndrome with second trimester maternal serum markers. Prenat Diagn 2002;22:1036-1039
4. Tongsong T, Wanapirak C, Sirivatanapa P, Piyamongkol W, Sirichotiyakul S, Yampochai A. Amniocentesis-related fetal loss: a cohort study. Obstet Gynecol 1998;92:64-67
5. NICHD National Registry for Amniocentesis Study Group. Midtrimester amniocentesis for prenatal diagnosis: safety and accuracy. JAMA 1976;236:1471-1476.
6. Porreco RP, Young PE, Resnik R, et al. Reproductive outcome following amniocentesis for genetic indications. Am J Obstet Gynecol 1982;143:653-660
7. Hanson FW, Tennant FR, Zorn EM, Samuels S. Analysis of 2136 genetic amniocenteses: experience of a single physician. Am J Obstet Gynecol 1985;152:436-443
8. Marthin T, Liedgren S, Hammar M. Transplacental needle passage and other risk-factors associated with second trimester amniocentesis. Acta Obstet Gynecol Scand 1997;76:728-732
9. Bombard AT, Powers JF, Carter S, Schwartz A, Nitowsky HM. Procedure-related fetal losses in transplacental versus nontransplacental genetic amniocentesis. Am J Obstet Gynecol 1995;172:868-872
10. Silver RK, Russell TL, Kambich MP, Leeth EA, MacGregor SN, Sholl JS. Midtrimester amniocentesis: influence of operator caseload on sampling efficiency. J Reprod Med 1998;43:191-195
11. Blessed WB, Lacoste H, Welch RA. Obstetrician-gynecologists performing genetic amniocentesis may be misleading themselves and their patients. Am J Obstet Gynecol 2001;184:1340-1344
12. Blackwell SC, Abundis MG, Nehra PC. Five-year experience with midtrimester amniocentesis performed by a single group of obstetricians- gynecologists at a community hospital. Am J Obstet Gynecol 2002;186:1130-1132
13. Ogle R, Jauniaux E, Pahal G, Dell E, Sheldrake A, Rodeck C. Serum screening for Down syndrome and adverse pregnancy outcomes: a case-controlled study. Prenat Diagn 2000;20:96-99
14. Van Rijn M, Van Der Schouw YT, Hagenaars AM, Visser GHA, Christiaens GCML. Adverse obstetric outcome in low- and high-risk pregnancies: predictive value of maternal serum screening. Obstet Gynecol 1999;94:929-934
15. Crandall BF, Howard J, Lebherz TB, Rubinstein L, Sample WF, Sarti D. Follow-up of 2000 second-trimester amniocenteses. Obstet Gynecol 1980;56:625-628
16. Brumfield CG, Lin S, Conner W, Cosper P, Davis RO, Owen J. Pregnancy outcome following genetic amniocentesis at 11-14 versus 16-19 weeks' gestation. Obstet Gynecol 1996;88:114-118
17. The Canadian Early and Mid-Trimester Amniocentesis Trial (CEMAT) Group. Randomised trial to assess safety and fetal outcome of early and midtrimester amniocentesis. Lancet 1998;351:242-247
18. Smidt-Jensen S, Permin M, Philip J, et al. Randomised comparison of amniocentesis and transabdominal and transcervical chorionic villus sampling. Lancet 1992;340:1237-1244
19. Crane JP, Kopta MM. Genetic amniocentesis: impact of placental position upon the risk of pregnancy loss. Am J Obstet Gynecol 1984;150:813-816
20. Saltvedt S, Almstrom H. Fetal loss rate after second trimester amniocentesis at different gestational age. Acta Obstet Gynecol Scand 1999;78:10-14
21. Laing FC, Frates MC. Ultrasound evaluation during the first trimester of pregnancy. In: Callen PW, ed. Ultrasonography in Obstetrics and Gynecology. Philadelphia: WB Saunders; 2000:105-145
22. Cederholm M, Haglund B, Axelsson O. Maternal complications following amniocentesis and chorionic villus sampling for prenatal karyotyping. BJOG 2003;110:392-399